3:45 AM | Friday | Sep 11, 2026
Lone Peak Global Investors LLC decreased its holdings in Johnson and Johnson (NYSE: JNJ) by 9.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,091 shares of the company's stock after selling 7,153 shares during the quarter. Johnson and Johnson
Read full articleLone Peak Global Investors LLC decreased its holdings in Johnson and Johnson (NYSE: JNJ) by 9.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,091 shares of the company's stock after selling 7,153 shares during the quarter. Johnson and Johnson
Read full article
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
Read full article
Generating $500 a month from dividends sounds straightforward until you see how wildly the required capital swings depending on which stocks you pick and which trade-offs you are willing to accept.
Read full article
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
Read full article
LIMERICK, Ireland--(BUSINESS WIRE)--Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies.
Read full article
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
Read full article
Ancora Advisors LLC lowered its stake in shares of Johnson and Johnson (NYSE: JNJ) by 8.5% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 229,968 shares of the company's stock after selling 21,326 shares during the
Read full article
Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Read full article
Johnson & Johnson NYSE: JNJ MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period, citing a portfolio shift toward cardiovascular products, operating-model changes and continued investment in differentiated technologies.
Read full article
These two are on the Dividend Kings list.
Read full article
A seven-holding portfolio promising $12,500 a month sounds straightforward until you examine whose money is actually funding some of those distributions, and why the highest-yielding positions have the weakest claim to keeping their promises.
Read full article
Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral...
Read full article
Johnson & Johnson (JNJ) reached $269.12 at the closing of the latest trading day, reflecting a -2.22% change compared to its last close.
Read full article
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
Read full article
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
Read full article
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
Read full article
On Tuesday morning's Squawk on the Street, Jim Cramer told viewers to step in on a mid-session drop in Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction).
Read full article
Medicare Part B premiums keep climbing, and Social Security checks keep shrinking to cover them. Three Dividend Kings with very different yields and coverage profiles could shift that math entirely in a retiree's favor.
Read full article
First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions TITUSVILLE, N.J., Sept. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA).
Read full article
JEPI's monthly paycheck looks irresistible until you see exactly what the fund surrenders to produce it. Three Dividend Kings quietly sidestep that tradeoff, and the difference compounds in ways most income investors never stop to calculate.
Read full article
Livforsakringsbolaget Skandia Omsesidigt lifted its position in Johnson and Johnson (NYSE: JNJ) by 4.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 222,206 shares of the company's stock after purchasing an additional 10,400 shares during the quarter. Johnson and Johnson comprises about
Read full article
Jefferies Financial Group Inc. lessened its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 8.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 68,010 shares of the company's stock after selling 6,617 shares during the quarter. Jefferies Financial Group Inc.
's
Fulcrum Asset Management LLP reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 9.0% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,815 shares of the company's stock after selling 2,061 shares during the period. Fulcrum Asset Management LLP's holdings
Read full article
Centaurus Financial Inc. lifted its position in Johnson and Johnson (NYSE: JNJ) by 49.5% in the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,384 shares of the company's stock after acquiring an additional 4,103 shares during the period. Centaurus Financial Inc.
's holdings in Johnson
Empowered Funds LLC raised its position in Johnson and Johnson (NYSE: JNJ) by 11.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 348,850 shares of the company's stock after purchasing an additional 36,477 shares during the quarter. Johnson and Johnson accounts
Read full article
Rakuten Investment Management Inc. boosted its holdings in Johnson and Johnson (NYSE: JNJ) by 10.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 393,806 shares of the company's stock after purchasing an additional 36,182 shares during the
Read full article
Equitable Holdings Inc. reduced its stake in Johnson and Johnson (NYSE: JNJ) by 15.1% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 144,824 shares of the company's stock after selling 25,728 shares during the quarter. Equitable Holdings Inc.
's holdings in Johnson and
Public Employees Retirement System of Ohio lowered its position in shares of Johnson and Johnson (NYSE: JNJ) by 7.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 983,704 shares of the company's stock after selling 75,986 shares during the quarter. Johnson
Read full article
MASTERINVEST Kapitalanlage GmbH trimmed its stake in shares of Johnson and Johnson (NYSE: JNJ) by 9.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,423 shares of the company's stock after selling 3,206 shares during the period.
Read full article
On Tuesday morning's Squawk on the Street, Jim Cramer told viewers to step in on a mid-session drop in Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction).
Read full article
Medicare Part B premiums keep climbing, and Social Security checks keep shrinking to cover them. Three Dividend Kings with very different yields and coverage profiles could shift that math entirely in a retiree's favor.
Read full article
First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions TITUSVILLE, N.J., Sept. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA).
Read full article
JEPI's monthly paycheck looks irresistible until you see exactly what the fund surrenders to produce it. Three Dividend Kings quietly sidestep that tradeoff, and the difference compounds in ways most income investors never stop to calculate.
Read full article
Livforsakringsbolaget Skandia Omsesidigt lifted its position in Johnson and Johnson (NYSE: JNJ) by 4.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 222,206 shares of the company's stock after purchasing an additional 10,400 shares during the quarter. Johnson and Johnson comprises about
Read full article
Fulcrum Asset Management LLP reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 9.0% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,815 shares of the company's stock after selling 2,061 shares during the period. Fulcrum Asset Management LLP's holdings
Read full article
Jefferies Financial Group Inc. lessened its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 8.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 68,010 shares of the company's stock after selling 6,617 shares during the quarter. Jefferies Financial Group Inc.
's
Centaurus Financial Inc. lifted its position in Johnson and Johnson (NYSE: JNJ) by 49.5% in the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,384 shares of the company's stock after acquiring an additional 4,103 shares during the period. Centaurus Financial Inc.
's holdings in Johnson
Empowered Funds LLC raised its position in Johnson and Johnson (NYSE: JNJ) by 11.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 348,850 shares of the company's stock after purchasing an additional 36,477 shares during the quarter. Johnson and Johnson accounts
Read full article
Rakuten Investment Management Inc. boosted its holdings in Johnson and Johnson (NYSE: JNJ) by 10.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 393,806 shares of the company's stock after purchasing an additional 36,182 shares during the
Read full article